152 related articles for article (PubMed ID: 7113804)
1. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Loh E; Kufe DW
Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
[TBL] [Abstract][Full Text] [Related]
3. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
4. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
6. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
7. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Kensler TW; Reck LJ; Cooney DA
Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
[No Abstract] [Full Text] [Related]
9. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
10. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Laval M; Azou Y; Giorgi D; Rosset R
Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
[TBL] [Abstract][Full Text] [Related]
11. The glutamine analog acivicin as antipyrimidine. Studies on the interrelationship between pyrimidine and urea synthesis in liver.
Pausch J; Rasenack J; Häussinger D; Holstege A; Gerok W
Adv Enzyme Regul; 1985; 24():233-43. PubMed ID: 3835821
[TBL] [Abstract][Full Text] [Related]
12. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
[TBL] [Abstract][Full Text] [Related]
13. Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis.
Kempe TD; Swyryd EA; Bruist M; Stark GR
Cell; 1976 Dec; 9(4 Pt 1):541-50. PubMed ID: 12870
[TBL] [Abstract][Full Text] [Related]
14. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
16. In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma.
Aoki T; Sebolt J; Weber G
Biochem Pharmacol; 1982 Mar; 31(6):927-32. PubMed ID: 7082374
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of Crithidia fasciculata carbamoyl phosphate synthetase II by the antitumor drug acivicin.
Aoki T; Oya H
Mol Biochem Parasitol; 1987 Mar; 23(2):173-81. PubMed ID: 3574357
[TBL] [Abstract][Full Text] [Related]
18. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
19. Hepatic carbamoyl phosphate metabolism. Role of cytosolic and mitochondrial carbamoyl phosphate in de novo pyrimidine synthesis.
Pausch J; Rasenack J; Häussinger D; Gerok W
Eur J Biochem; 1985 Jul; 150(1):189-94. PubMed ID: 4018077
[TBL] [Abstract][Full Text] [Related]
20. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper ES; Vale K; Williams LJ; Martin DS; Young CW
Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]